GLP-1 drugs such as semaglutide are showing potential in reducing alcohol consumption and cravings, but researchers say larger trials are still needed.
Medications widely used for weight management, including semaglutide, are drawing growing scientific interest for a potential additional benefit: reducing cravings for alcohol and possibly other addictive substances.
These medicines belong to a class known as GLP-1 receptor agonists (GLP-1RAs). Drugs such as semaglutide are approved for conditions including type 2 diabetes and obesity, and they work partly by regulating appetite and increasing feelings of fullness.
Researchers are now investigating whether their effects extend beyond appetite control to the brain’s reward system, which plays an important role in cravings and addictive behaviours.
Evidence for Reduced Alcohol Cravings
Recent human studies have provided encouraging early evidence. A randomized clinical trial published in 2026 found that semaglutide reduced heavy-drinking days among people with alcohol use disorder and obesity when used alongside cognitive behavioural therapy. Participants receiving semaglutide experienced a greater reduction in heavy-drinking days than those receiving placebo.
Another randomized trial found that low-dose semaglutide reduced alcohol craving and the amount of alcohol consumed in a controlled laboratory setting. The study also reported a reduction in cigarette consumption among a subgroup of participants who smoked. However, not all measures of alcohol consumption were affected.
A 2026 systematic review of GLP-1 drugs and substance-use disorders found consistent evidence from animal studies that these medicines can reduce substance intake and drug-seeking behaviours. Human evidence was more limited, particularly for substances other than alcohol, with researchers stressing that clinical studies remain relatively small and short.
How Could GLP-1 Drugs Affect Cravings?
Scientists believe GLP-1 receptors are involved not only in appetite regulation but also in brain pathways associated with reward and motivation.
This has led researchers to explore whether GLP-1 medicines could reduce the rewarding effects of alcohol and other substances, potentially lowering the intensity of cravings. However, the exact mechanisms are still being investigated.
While the findings are promising, researchers caution that GLP-1 medicines are not yet established as a general treatment for addiction. Larger and longer randomized clinical trials are needed to determine their effectiveness and safety for alcohol use disorder and other substance-use disorders.
For now, the research suggests that medicines originally developed for metabolic conditions could have broader effects on the brain’s reward system — opening a new area of investigation in addiction treatment.
Also Read :Can Stale Roti Help With Weight Loss?
Today's E-Paper